Suitors Knock on GW Pharma's Door for Pot-Based Drug

Sep 08, 2016


GW Pharmaceuticals Plc is working with an investment bank after drug companies were said to have expressed interest in buying the company, according to a Reuters article.

GW Pharma makes marijuana-based epilepsy treatments, and it appears to be a target for larger pharma companies because of its key drug, Epidolex, the story said. The company has hired investment bank Morgan Stanley to help handle the inquiries, but it's not necessarily interested in any acquisition offers.

Read the Reuters article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments